|
Match
|
Document |
Document Title |
|
|
US20130109687 |
METHODS OF TREATING HIV INFECTION: INHIBITION OF DNA DEPENDENT PROTEIN KINASE
Methods of treating HIV-1 infection/AIDS in a patient infected with an HIV-1 virus comprising providing a DNA-PK inhibitor to the patient are provided herein. In one embodiment the DNA-PK... |
|
|
US20120202801 |
METHODS FOR TREATING BREAST CANCER
Methods for treating breast cancer involving the administration of a compound that selectively inhibits pathological production of human vascular endothelial growth factor (VEGF) are described.... |
|
|
US20110280808 |
Novel Compounds for the Treatment of Diseases Associated with Amyloid or Amyloid-Like Proteins
The present invention relates to novel compounds that can be employed in the treatment of a group of disorders and abnormalities associated with amyloid protein, such as Alzheimer's disease, and... |
|
|
US20150087630 |
METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER
Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R3, R5 and R6 are as defined herein. |
|
|
US20130261104 |
METHODS OF USE OF DIAZACARBAZOLES FOR TREATING CANCER
Methods of use of compounds of formula (I) for treating cancer: wherein X, Y, X, R3, R5 and R6 are as defined herein. |
|
|
US20120157400 |
METHODS FOR TREATING KAPOSI SARCOMA
Methods for treating Kaposi's sarcoma involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as... |
|
|
US20080234236 |
REDUCTION OF ADVERSE EVENTS AFTER PERCUTANEOUS INTERVENTION BY USE OF A THROMBIN RECEPTOR ANTAGONIST
Disclosed are methods of preventing adverse clinical events in a patient undergoing a percutaneous coronary intervention procedure or a peripheral percutaneous interventional procedure comprising... |
|
|
US20120157402 |
METHODS FOR TREATING BRAIN TUMORS
Methods for treating brain tumors involving the administration of a compound that selectively inhibits pathological production of human VEGF are described. The compound can be administered as a... |
|
|
US20130102597 |
COMPOUNDS AND METHODS FOR TREATING INFLAMMATORY AND FIBROTIC DISORDERS
Disclosed are compounds and methods for treating inflammatory and fibrotic disorders, including methods of modulating a stress activated protein kinase (SAPK) system with an active compound,... |
|
|
US20150005300 |
PYRIDAZINONE COMPOUNDS AND METHODS FOR THE TREATMENT OF CYSTIC FIBROSIS
The invention relates to a compound of having the following formulae and methods of treating cystic fibrosis: |
|
|
US20120178707 |
METHODS FOR TREATING PROSTRATE CONDITIONS
Methods for treating prostate cancer involving the administration of a compound that selectively inhibits pathological production of human vascular endothelial growth factor (VEGF) are described.... |
|
|
US20150133442 |
METHODS AND COMPOSITIONS FOR THE INHIBITION OF PIN1
The invention features compositions and methods for inhibiting the Pin1 protein, and the treatment of disorders characterized by elevated Pin1 levels. |
|
|
US20150133443 |
Thiazolyl- And Oxazolyl-Isoquinolinones And Methods For Using Them
The present invention relates to substituted thiazolyl- and oxazolyl-isoquinolinones that act, for example, as modulators of poly(ADP-ribose) polymerase (PARP). The present invention also relates... |
|
|
US20130059843 |
Thiazolyl- and Oxazolyl-Isoquinolinones and Methods for Using Them
The present invention relates to substituted thiazolyl- and oxazolyl-isoquinolinones that act, for example, as modulators of poly(ADP-ribose) polymerase (PARP). The present invention also relates... |
|
|
US20140343051 |
METHODS TO MODULATE ACUTE MYELOID LEUKEMIA STEM/PROGENITOR CELL EXPANSION AND/OR DIFFERENTIATION
Novel methods for modulating acute myeloid leukemia stem/progenitor cell expansion and/or differentiation are disclosed. These methods are based on the use of aryl hydrocarbon receptor (AhR)... |
|
|
US20130136809 |
7-HYRDROXYFRULLANOLIDE ITS ANALOGS FOR PREVENTION CONTROL AND TREATMENT OF METABOLIC DISORDERS
The invention discloses biologically active ingredient(s) selected from 7-hydroxyfrullanolide, its analogs, the ex-tract(s) and fraction(s) standardized to 7-hydroxyfrullanolide or its analogs or... |
|
|
US20120040966 |
ANTI-VIRAL COMPOUNDS, TREATMENT, AND ASSAY
The compounds provided herein are suitable for inhibiting a virus in a patient and for treating a patient suffering from a viral infection such as an influenza virus. Also provided is a method for... |
|
|
US20120022046 |
Thienopyridine Derivatives for the Treatment and Prevention of Dengue Virus Infections
Methods and pharmaceutical compositions for treating viral infections, by administering certain thienopyridine derivative compounds in therapeutically effective amounts are disclosed. Methods of... |
|
|
US20140371207 |
CHEMOKINE RECEPTOR ANTAGONISTS AND METHODS OF USE THEREOF
Disclosed are novel compounds and a method of treating a disease associated with aberrant leukocyte recruitment and/or activation. The method comprises administering to a subject in need an... |
|
|
US20150148318 |
METHOD FOR INHIBITING GROWTH OF CANCER CELLS
A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Akt1,... |
|
|
US20110160190 |
CARBOLINE DERIVATIVES USEFUL IN THE INHIBITION OF ANGIOGENESIS
In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and methods for their use provided. In one aspect of the... |
|
|
US20130171103 |
METHODS FOR TREATING VIRAL CONDITIONS
Compounds that selectively inhibit viral replication or the production of viral RNA or DNA, viral protein or virus induced cytopathic effects and compositions comprising such Compounds are... |
|
|
US20120202763 |
METHODS FOR TREATING CANCER AND NON-NEOPLASTIC CONDITIONS
Compounds that selectively inhibit pathological production of human vascular endothelial growth factor (VEGF) and compositions comprising such Compounds are described. Compounds that inhibit viral... |
|
|
US20120129841 |
CARBOLINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER AND OTHER DISEASES
In accordance with the present invention, compounds that inhibit the expression of VEGF post-transcriptionally have been identified, and compositions, and methods for the administration and use of... |
|
|
US20140080824 |
STRUCTURE-GUIDED IDENTIFICATION OF BINDING INTERACTIONS OF HUMAN LAMININ RECEPTOR PRECURSOR WITH LAMININ AND IDENTIFICATION OF COMPOUNDS THAT AFFECT BINDING
The present invention pertains to compounds which interfere with the binding of laminin to the laminin receptor (LamR). Such compounds are useful for treating diseases such as cancer, Alzheimer's... |
|
|
US20110112088 |
PYRAZOLES FOR THE TREATMENT OF OBESITY AND OTHER CNS DISORDERS
This invention relates to compounds of the formula: to compositions containing these compounds, and to methods of treatment employing the compounds and compositions. |
|
|
US20110105494 |
HETEROARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2A RECEPTOR ANTAGONISTS
This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease. wherein X, R2, R3, and R4 are... |
|
|
US20110105493 |
HETEROCYCLYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS
This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease. wherein X, R2, R3, and R4 are... |
|
|
US20110105492 |
ARYL SUBSTITUTED ARYLINDENOPYRIMIDINES AND THEIR USE AS HIGHLY SELECTIVE ADENOSINE A2a RECEPTOR ANTAGONISTS
This invention relates to a novel arylindenopyrimidine, A, and its therapeutic and prophylactic uses. Disorders treated and/or prevented include Parkinson's Disease wherein X, R2, R3, and R4 are... |
|
|
US20110312956 |
ARYLINDENOPYRIMIDINES WITH REDUCED hERG CHANNEL BINDING
This invention provides novel arylindenopyrimidines of the Formula (I), and pharmaceutical compositions comprising same, useful for treating disorders ameliorated by antagonizing adenosine A1... |
|
|
US20150191495 |
ANTIDIABETIC TRICYCLIC COMPOUNDS
Novel compounds of the structural formula (I), and the pharmaceutically acceptable salts thereof, are agonists of G-protein coupled receptor 40 (GPR40) and may be useful in the treatment,... |
|
|
US20090075937 |
LHRH ANTAGONISTS FOR THE TREATMENT OF LOWER URINARY TRACT SYMPTOMS
The present invention provides at least one LHRH antagonist for the treatment or prophylaxis of at least one lower urinary tract symptom in mammals which is to be administered in an intermediate... |
|
|
US20150051204 |
COMPOUNDS FOR TREATMENT OF METABOLIC SYNDROME
Present invention refers to new compounds of formula I or II, its synthesis and its use in the treatment of metabolic syndrome, particularly for the treatment of type I or type II diabetes and/or... |
|
|
US20130165412 |
CANNABINOID RECEPTOR MODULATORS
The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further... |
|
|
US20120214766 |
CANNABINOID RECEPTOR MODULATORS
The present invention relates to certain compounds of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the cannabinoid CB2 receptor. The present invention further... |
|
|
US20090029984 |
SYNERGISTIC COMBINATION FOR THE TREATMENT OF PAIN (CANNABINOID RECEPTOR AGONIST AND OPIOID RECEPTOR AGONIST)
The invention relates to a pharmaceutical dosage form comprising an analgesic combination for simultaneous or sequential use which comprises a peripherally restricted cannabinoid CB1 receptor... |
|
|
US20130123235 |
Tricyclic Compounds and Methods of Making and Using Same
The invention provides tricyclic compounds and their use in treating medical disorders, such as obesity. Pharmaceutical compositions and methods of making various tricyclic compounds are provided.... |
|
|
US20110112052 |
SPIRO-OXINDOLE MDM2 ANTAGONISTS
Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists... |
|
|
US20110136802 |
SHIP1 MODULATORS AND METHODS RELATED THERETO
Compounds of structure (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein X, R1, R2, R3, R4, R5, R6 and R7 are as defined herein. Such compounds have activity as... |
|
|
US20130116219 |
ANTIMICROBIAL CARBOLINE COMPOUNDS
The invention provides compositions comprising carboline compounds for treating infections such as viral conjunctivitis. The invention also provides methods for treating of other infections,... |
|
|
US20110263581 |
FUSED TRICYCLIC COMPOUNDS AS SERINE-THREONINE PROTEIN KINASE AND PARP MODULATORS
The invention relates in part to molecules having certain biological activities that include, but are not limited to, inhibiting cell proliferation, modulating protein kinase activity and... |
|
|
US20130109686 |
ISOINDOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
The present invention is directed to isoindolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1... |
|
|
US20130102599 |
PYRAZOLO [4,3-C] CINNOLIN-3-ONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
The present invention is directed to pyrazolo[4,3-c]cinnolin-3-one compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in... |
|
|
US20120252828 |
PYRIDOQUINAZOLINONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which... |
|
|
US20120196845 |
QUINOLINONE-PYRAZOLONE M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which... |
|
|
US20100069355 |
Analogs of Indole-3-Carbinol and Their Use as Agents Against Infection
Compounds useful as antibacterial agents are provided. The compounds are analogs of indole-3-carbinol and have a backbone selected from dihydroindolo[2,3-b]carbazole, 2,2′-diindolylmethane,... |
|
|
US20110212929 |
Protein Kinase Inhibitors
Protein kinase inhibitors are disclosed having utility in the treatment of protein kinase-mediated diseases and conditions, such as cancer. The compounds of this invention have the following... |
|
|
US20150065498 |
N-LINKED LACTAM M1 RECEPTOR POSITIVE ALLOSTERIC MODULATORS
The present invention is directed to N-linked lactam compounds of general formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which... |
|
|
US20130190273 |
Methods for Treating Amyotrophic Lateral Sclerosis Using Pro-Neurogenic Compounds
This technology relates generally to compounds and methods for stimulating neurogenesis (e.g., post-natal neurogenesis, including post-natal hippocampal and hypothalamic neurogenesis) and/or... |
|
|
US20140179671 |
FUSED RING AZADECALIN GLUCOCORTICOID RECEPTOR MODULATORS
The present invention provides a novel class of fused ring azadecalin compounds and methods of using the compounds as glucocorticoid receptor modulators. |